New Directions in Treatment of Hypoparathyroidism

• Autores: Gaia Tabacco, John P. Bilezikian
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 47, Nº. 4, 2018 (Ejemplar dedicado a: Hypoparathyroidism), págs. 901-915
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The history of parathyroid hormone (PTH) replacement therapy for hypoparathyroidism begins in 1929. In 2015, the Food and Drug Administration approved recombinant human PTH(1–84) [rhPTH(1–84)] as a treatment for hypoparathyroidism. Long-term studies of rhPTH(1–84), up to 6 years, have demonstrated continued efficacy of this replacement agent. Approaches to optimize PTH treatment in hypoparathyroidism include subcutaneous pump delivery systems, long-lived carrier molecules, and long-acting PTH analogues that show promise to prolong efficacy. Calcilytic compounds have been explored as a treatment for autosomal dominant hypocalcemia. Calcilytics are negative modulators of the calcium-sensing receptor and may present a therapeutic opportunity to increase endogenous PTH synthesis and secretion.